Skip to main content
ZERIA PHARMCEUTICAL CO., LTD. logo

ZERIA PHARMCEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4559 ISIN · JP3428850006 T Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country JP Japan
Listing T 4559

About ZERIA PHARMCEUTICAL CO., LTD.

https://www.zeria.co.jp/english/

Zeria Pharmaceutical Co., Ltd. is a comprehensive healthcare company established in 1955. The company's operations are structured around two primary business segments: Ethical Pharmaceuticals and Consumer Healthcare. Its activities include the research, development, manufacturing, and distribution of a diverse range of products, including prescription medications, over-the-counter drugs, and other health-related goods. Zeria focuses on developing innovative pharmaceutical products to contribute to the health of people globally.

Recent filings

Filing Released Lang Actions
取締役候補者の選任に関するお知らせ
Regulatory Filings
2026-05-08 Japanese
剰余金の配当（増配）に関するお知らせ
Regulatory Filings
2026-05-08 Japanese
2026年３月期 決算短信〔日本基準〕（連結）
Regulatory Filings
2026-05-08 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly cites '金融商品取引法第24条の５の２第１項' (Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act). It serves as an officer certification confirming the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report (like a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 72
2025-11-07 Japanese
半期報告書－第72期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains comprehensive financial statements, including the balance sheet, for the interim period ending September 30, 2025. It is a formal regulatory filing containing substantive financial data, which fits the definition of an Interim/Quarterly Report (IR). H1 2026
2025-11-07 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director. The 'Reason for Submission' explicitly states that the report is filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the 71st Annual General Meeting (AGM) held on June 27, 2025. The content details the resolutions, including the dividend amount and the election of directors, along with the voting results (approvals, rejections). This structure perfectly matches the definition of reporting the results of a shareholder meeting vote. The most specific code for reporting voting results is DVA (Declaration of Voting Results & Voting Rights Announcements). Although it relates to the AGM, the core content is the voting outcome, not the AGM presentation materials (AGM-R).
2025-07-03 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.